AGP Executive Report
Last update: an hour agoIcelandic Biotech: Alvotech won US FDA approval for a new SIMLANDI manufacturing process at its Reykjavík facility, more than doubling drug-substance output per batch while maintaining quality standards. The change could free capacity for other medicines. Obesity Care: A European procedure has backed extending QSIVA, a weight-management medicine, to adolescents aged 12 and older. Iceland is among 17 countries expected to issue national decisions; the treatment is already approved there for adults. Pension Security: Iceland received an “A” rating in the 2026 global pension index, scoring 84.0 and ranking among the world’s strongest systems for retirement income.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.